Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure
A. V. Rudakova,
N. I. Brico,
Yu. V. Lobzin,
L. S. Namazova-Baranova,
S. N. Avdeev,
M. P. Kostinov,
V. A. Korshunov,
I. V. Fomin https://doi.org/10.18087/cardio.2023.5.n2378
Abstract
Aim To analyze the cost-effectiveness of pneumococcal vaccination in 40- and 65-year-old patients with chronic heart failure (CHF).
Material and methods Analysis was performed by Markov modeling from the perspective of the healthcare system. The evaluation was based on Russian epidemiological data taking into account results of international studies. The analyzed schedule of vaccination included one dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent polysaccharide vaccine (PPSV23) after one year and vaccination with only one dose of PCV13. The time horizon of the study was 5 years. Costs and life expectancy were discounted at 3.5% per year.
Results The cost-effectiveness of vaccination for both 65-year-old and 40-year-old CHF patients is very high: the incremental cost of one additional QALY (Quality-Adjusted Life Year) for PCV13+PPSV23 vaccination is 113.24 thousand rubles, while vaccination with PCV13 entails a reduction in costs by 556.50 rubles per one vaccinated patient. For vaccination of 40-year-old CHF patients with PCV13+PPSV23, the incremental costs per 1 QALY will be 519.72 thousand rubles, while for vaccination with PCV13 it will be 99.33 thousand rubles.
Conclusion Pneumococcal vaccination of CHF patients reduces the associated morbidity and mortality and is highly cost effective.
Supporting agencies: This study has a number of limitations. Specifically, the study did not take into account the decrease in the incidence of invasive pneumococcal infections due to vaccination. Conflict of interest The publication was prepared using materials of a study supported by OOO Pfizer Innovations. The authors did not receive financial support from OOO Pfizer Innovations related with the preparation of this article. The article reflects the position of the authors, which may differ from the position of OOO Pfizer Innovations.
About the Authors
A. V. Rudakova
Children’s Research and Clinical Center for Infectious Diseases, St. Petersburg
Russian Federation
Russian Federation
Dr. Sci. (Pharm), Professor, Senior researcher of Department of the organization of medical care in the Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency, Professor of Department of Management and Economics of Pharmacy, St. Petersburg Chemical and Pharmaceutical University
N. I. Brico
Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
the RAS Academician, Dr. Sci. (Med), Professor, Head of Epidemiology and Evidence Based Medicine Department in the I.M. Sechenov First Moscow State Medical University (Sechenov University), Chief External Epidemiologist of the Ministry of Health of the Russian Federation
Yu. V. Lobzin
Children’s Research and Clinical Center for Infectious Diseases, St. Petersburg
Russian Federation
Russian Federation
the RAS Academician, Dr. Sci. (Med), Professor, President of the Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency, Head of the Department of Infectious Diseases of the North-Western State Medical University named after I. I. Mechnikov, Chief External Specialist in Infectious Diseases in Children
L. S. Namazova-Baranova
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
the RAS Academician, Dr. Sci. (Med), Professor. Head of the Department of Faculty Pediatrics in Pediatric Department of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Head of the Research Institute of Pediatrics and Children's Health in the Central Clinical Hospital of the RAS, Chief External pediatric specialist in preventive medicine
S. N. Avdeev
Research Institute of Pulmonology, Moscow
Russian Federation
Russian Federation
the RAS Academician, Dr. Sci. (Med), Professor, Head of the Department of Pulmonology in the I.M. Sechenov First Moscow State Medical University (Sechenov University); Head of the Clinical Department of the Federal State Budgetary Institution "Research Institute of Pulmonology" of the Federal Medical and Biological Agency of Russia, Chief External Pulmonologist
M. P. Kostinov
Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
the RAS corresponding member, Dr. Sci. (Med), Professor, Head of the Laboratory of Vaccine Prevention and Immunotherapy of Allergic Diseases in Research Institute of Vaccines and Serums named after I. I. Mechnikov, Professor of the Department of Epidemiology in the I.M. Sechenov First Moscow State Medical University (Sechenov University)
V. A. Korshunov
Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Cand. Sci. (Med), Аssociate Professor of Epidemiology and Evidence Based Medicine Department
I. V. Fomin
Privolzhsky Research Medical University, Nizhny Novgorod
Russian Federation
Russian Federation
Dr. Sci. (Med), Professor, Head of the Department of Hospital Therapy and General Medical Practice named after V.G. Vogralik
References
1. Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S., Sukhorukova M.V., Yatsyshina S.B. et al. Etiology of community-acquired pneumonia in patients with chronic heart failure. Russian Pulmonology. 2019;29(3):293–301. DOI: 10.18093/0869-0189-2019-29-3-293-301
2. Briko N.I., Korshunov V.A., Lomonosov K.S. Pneumococcal infection in Russia: state of the issue. Annals of the Russian academy of medical sciences. 2021;76(1):28–42. DOI: 10.15690/vramn1404
3. Polyakov D.S., Fomin I.V., Valikulova F.Yu., Vaisberg A.R., Kraiem N. Evaluation of the impact of community-acquired pneumonia on short-term and long-term prognosis in a patient with chronic decompensated heart failure. Therapeutic Archive. 2016;88(9):17–22. DOI: 10.17116/terarkh201688917-22
4. Polyakov D.S., Fomin I.V., Vaisberg A.R., Valikulova F.Yu., Ivanchenko E.Yu., Kraiem N. Predictors of community-acquired pneumonia in patients with acute decompensated heart failure: the results of the analysis of the hospital sample EPOHA-D-CHF. Therapeutic Archive. 2018;90(4):35–41. DOI: 10.26442/terarkh201890435-41
5. Ong LT. The Association Between Pneumonia and Heart failure. Clinical Pulmonary Medicine. 2020;27(5):125–30. DOI: 10.1097/CPM.0000000000000371
6. Jobs A, Simon R, de Waha S, Rogacev K, Katalinic A, Babaev V et al. Pneumonia and inflammation in acute decompensated heart failure: a registry-based analysis of 1939 patients. European Heart Journal: Acute Cardiovascular Care. 2018;7(4):362–70. DOI: 10.1177/2048872617700874
7. Arutyunov A.G., Dragunov D.O., Arutyunov G.P., Rylova A.K.,Pashkevich D.D., Viter K.V. et al. First open study of syndrome of acute decompensation of heart failure and concomitant diseases in Russian Federation: independent registry ORAKUL. Kardiologiia. 2015;55(5):12–21.
8. Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP et al. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. Journal of the American College of Cardiology. 2021;77(16):1961–73. DOI: 10.1016/j.jacc.2021.03.001
9. Brotherton AL, Shah R. Recent Updates to the Advisory Committee On Immunization Practices Recommendations for Pneumococcal and Herpes Zoster Vaccination. Rhode Island Medical Journal (2013). 2020;103(6):34–7. PMID: 32752563
10. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 2014;63(37):822–5. PMID: 25233284
11. Marques Antunes M, Duarte GS, Brito D, Borges M, Costa J, Ferreira JJ et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and metaanalysis. European Heart Journal - Quality of Care and Clinical Outcomes. 2021;7(1):97–106. DOI: 10.1093/ehjqcco/qcaa030
12. Marra F, Zhang A, Gillman E, Bessai K, Parhar K, Vadlamudi NK. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;99:204–13. DOI: 10.1016/j.ijid.2020.07.038
13. Gupta N, Verma R, Dhiman RK, Rajsekhar K, Prinja S. Cost-Effectiveness Analysis and Decision Modelling: A Tutorial for Clinicians. Journal of Clinical and Experimental Hepatology. 2020;10(2):177–84. DOI: 10.1016/j.jceh.2019.11.001
14. Gusev A.V. Prospects for the further development of the medical statistics service through the transition to management based on data. Medical doctor and information technologies. 2018;2:6–22.
15. Kobyakova O.S., Polikarpov A.V., Golubev N.A., Ryabkov I.V., Lisnenko A.A. The transformation of medical statistic during pandemic of new coronavirus infection (COVID-19). Problems of Social Hygiene Public Health and History of Medicine. 2021;29(6):1439–45. DOI: 10.32687/0869-866X-2021-29-6-1439-1445
16. Romanenko V.V., Somova A.V. Epidemiologic Characteristics of Community-Acquired Pneumonia in Sverdlovsk Region. Epidemiology and Vaccinal Prevention. 2014;2(75):59–65.
17. Chuchalin A.G., Onishchenko G.G., Kolosov V.P., Kurganova O.P., Tezikov N.L., Manakov L.G. et al. Anti-epidemic activities to prevent pneumococcal infections in flooded areas of the Amur region. Russian Pulmonology. 2015;25(3):303–11. DOI: 10.18093/0869-0189-2015-25-3-303-311
18. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions. Open Forum Infectious Diseases. 2014;1(1):ofu024. DOI: 10.1093/ofid/ofu024
19. Dirmesropian S, Liu B, Wood JG, MacIntyre CR, McIntyre P, Karki S et al. Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy. Epidemiology and Infection. 2019;147:e118. DOI: 10.1017/S0950268818003473
20. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Diseases. 2017;65(11):1806–12. DOI: 10.1093/cid/cix647
21. Federal State Statistics Service. Women and men of Russia. Statistical compendium.-M.: Rosstat;2020. - 239 p. ISBN 978-5-89476-501-3
22. Ministry of Health of Russian Federation. Clinical guidelines. Community-acquired pneumonia in adults. ID:654. Av. at: https://cr.minzdrav.gov.ru/recomend/654_1. 2021.
23. Muravyev A.A., Chagaryan A.N., Ivanchik N.V., Kurkova A.A., Tsvetkova I.A., Kozlov R.S. et al. The prevalence of circulating S. pneumoniae serotypes in people older than 18 years: healthy carriers, patients with acute otitis media, community-acquired pneumonia, and invasive pneumococcal infections (epidemiological study “SPECTRUM”). Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(4):275–81. DOI: 10.36488/cmac.2019.4.275-281
24. Feldman C, Dlamini SK, Madhi SA, Meiring S, von Gottberg A, de Beer JC et al. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLOS ONE. 2020;15(1):e0227945. DOI: 10.1371/journal.pone.0227945
25. Huijts SM, van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444–9. DOI: 10.1016/j.vaccine.2017.01.071
26. Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. PLOS Medicine. 2020;17(10):e1003326. DOI: 10.1371/journal.pmed.1003326
27. Macroeconomics and health: investing in health for economic development; report of the Commission on Macroeconomics and Health. Sachs J, Weltgesundheitsorganisation, editors-Geneva: World Health Organization;2001. - 202 p. ISBN 978-92-4-154550-1
28. Iino H, Hashiguchi M, Hori S, Fu S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLoS One. 2022;17(4):e0266934. doi: 10.1371/journal.pone.0266934
Review
For citations:
Rudakova A.V., Brico N.I., Lobzin Yu.V., Namazova-Baranova L.S., Avdeev S.N., Kostinov M.P., Korshunov V.A., Fomin I.V. Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiia. 2023;63(5):19-26. https://doi.org/10.18087/cardio.2023.5.n2378
Views:
860
Email this article 
Post a Comment 
